Open Label Ketamine Treatment for Major Depressive Disorder in Veterans

Ketamine

Brief Summary

Medically healthy Veterans ages 21-75 that have been diagnosed with Depression will get up to 6 treatments of Ketamine infusions, weekly. After treatment is completed, follow up will occur at 1 month, 3 months, and 6 months after completion of infusions to evaluate the longer term effects of ketamine.

Intervention / Treatment

  • Ketamine (DRUG)
    0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval

Condition or Disease

  • Major Depressive Disorder

Phase

  • Phase 2

    • Study Design

    Study type: INTERVENTIONAL
    Status: Completed
    Study results: No Results Available
    Age: 21 Years to 75 Years
    Enrollment: 11 (ACTUAL)
    Funded by: U.S. Fed
    Allocation: N/A
    Primary Purpose: Treatment

    Masking

    Clinical Trial Dates

    Start date: Jan 31, 2017 ACTUAL
    Primary Completion: Sep 26, 2018 ACTUAL
    Completion Date: Sep 26, 2018 ACTUAL
    Study First Posted: Feb 15, 2017 ACTUAL
    Results First Posted: Aug 31, 2020
    Last Updated: Sep 15, 2023

    Sponsors / Collaborators

    Lead Sponsor: VA Connecticut Healthcare System
    Responsible Party: N/A

    Location

    West Haven, Connecticut, USA

    A total of 25 depressed subjects between the ages of 21-75 who have current major depressive disorder without psychotic features by DSM-5 will be recruited. Subjects will be accepted into the protocol after an opportunity to review and provide voluntary written informed consent and completion of a comprehensive medical and psychiatric history, physical examination, mental status examination, and routine laboratory assessments. Patients will be recruited in outpatient settings to the Refractory Depression Clinic. Providers or Refractory Depression consult team will be informed if the patient may be eligible for participation in the ketamine protocol. Subjects must have established care in the VA Connecticut Healthcare System. If the Veteran is interested, a screening visit for further evaluation for the ketamine protocol will be scheduled. Veterans will receive up to 6 infusions for ketamine weekly, per PI discretion. The primary goal of this proposal is to test the effectiveness of repeated ketamine treatment (0.5 mg/kg; once or twice a week for up to 6 weeks; up to a total of 6 ketamine infusions). An open-label trial will be conducted that will include up to 25 Veterans with MDD with a follow-up of 6 months. This open-label trial will allow us to examine the safety and tolerability of the ketamine treatment in this population and the long-term effects. All patients will receive usual standard care during this trial.

    Participant Groups

    • Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.

    Eligibility Criteria

    Sex: All
    Minimum Age: 21
    Maximum Age: 75
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    1. Male or female, 21-75 years old
    2. Current major depressive disorder without psychotic features by DSM-5
    3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 20
    4. Able to provide written informed consent

    Exclusion Criteria:

    1. Current or past history of psychotic features or psychotic disorder
    2. Current or past history of delirium or dementia
    3. Current uncontrolled hypertension (systolic BP \> 170 mm Hg or diastolic BP \> 100 mm Hg)
    4. Unstable medical condition or allergy to ketamine or lorazepam---clinically determined by a physician
    5. Pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential
    6. Positive opioid or illicit drug screen test (except marijuana)

    Primary Outcomes

    • MADRS is a standardized instrument to ascertain depressed mood and neurovegetative signs and symptoms of a major depressive episode.

    • A patient rated depression instrument

    • Standardized instrument to evaluate anxiety severity

    • Widely used instrument which asses overall severity of illness on a 1-7 point scale, with 1 indicating, not at all ill and 7 indicating among the most extremely ill patients

    • The BPRS is a standardized instrument that contains scales assessing psychotic symptoms including positive and negative symptoms, activation and emotional distress.

    • The CADSS has self and interviewer-administered items including 5 subscales, generated a priori, evaluating dissociation including altered environmental perception, time perception, spatial/body perception, derealization and memory impairment.

    • The VAS includes scales for anxiety, drowsiness, high irritability, anger and sadness. The scales are 100 mm lines marked by subjects at a point corresponding to the apparent intensity of the feeling state (0 = none, to 100 = most ever).

    • The TLFB is a standardized measure utilized for collecting information on daily alcohol use as well as other substance use.

    • The C-SSRS has both lifetime/recent and since last visit versions. The "Lifetime/Recent" version gathers information on lifetime history of suicidality and recent suicidal ideation/self-injurious behavior. The "Since Last Visit" version of the C-SSRS asks about any suicidal thoughts or behaviors the subject has exhibited since the last time administered the C-SSRS.

    • The Q-LES-Q is a self-report measure of quality of life.

    • A standard computerized battery will be done to assess cognitive ability post treatment of ketamine. The battery will include a wide range on cognitive tasks including but not limited to attention, learning, and working memory. While it is know ketamine causes acute cognitive effects, the longer-term effects of ketamine are not known. When the cognitive battery is being conducted on test days it will be done at the end of the test day, to eliminate the confounding effects of acute treatment of ketamine..

    More Details

    NCT Number: NCT03053830
    Acronym: Ket-MDD
    Other IDs: MR0012
    Study URL: https://clinicaltrials.gov/study/NCT03053830
    Last updated: Sep 29, 2023